Close Menu

artificial intelligence

Some partners are implementing their solutions on the Azure cloud while others will accept output from Microsoft's genomics pipeline as input into their solutions.

With an SBIR Phase II grant in hand, Michigan startup Parabricks is adding both speed and AI to variant calling as it eyes a Series A round next year.

The chatbot developed with Clear Genetics follows up with patients after genetic testing and educates family members at risk for inheriting the same mutations.

The companies announced a strategic venture to provide comprehensive biomarker profiling to empower clinical trials in the immuno-oncology space.

Franklin, an AI-driven variant classification tool, is helping Sanford Imagenetics reduce variants of unknown significance in its new ACMG-59 genotyping test.

While "genomical" has not supplanted "astronomical" in the lexicon, geneticist Gene Robinson believes data scientists understand the sheer size of genomic information.

As part of an NIH SBIR grant, Genomenon is automating the curation of medical literature in its Mastermind variant interpretation software.

Built by two of the creators of Nextflow, former Techstars company Lifebit makes scaleable genomic analysis technology that runs in the cloud.

IBM's supercomputing platform will continue to provide AI support to advanced cancer patients at VA medical centers for at least another year.

NuMedii will use its AI technology in combination with single-cell data to identify biomarkers and therapeutics for idiopathic pulmonary fibrosis.

Pages

Three genetic testing companies form a coalition to influence how Congress considers genetic privacy, The Hill reports.

University of California, San Diego researchers investigate how skin care products influence the skin microbiome, Scientific American reports.

The Wall Street Journal examines billing codes used by uBiome.

In PNAS this week: links between lung adenocarcinoma and lncRNA, algorithm to impute and cluster Hi-C interaction profiles from single cells, and more.